Interstate variation in trends of psychotropic medication use among Medicaid-enrolled children in foster care  by Rubin, David et al.
Children and Youth Services Review 34 (2012) 1492–1499
Contents lists available at SciVerse ScienceDirect
Children and Youth Services Review
j ourna l homepage: www.e lsev ie r .com/ locate /ch i ldyouthInterstate variation in trends of psychotropic medication use among
Medicaid-enrolled children in foster care☆,☆☆
David Rubin a,b,c,⁎, Meredith Matone a,⁎⁎, Yuan-Shung Huang c, Susan dosReis d,
Chris Feudtner a,b,c, Russell Localio e
a PolicyLab, The Children's Hospital of Philadelphia, Philadelphia, PA, United States
b Department of Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
c Division of General Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, United States
d Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States
e Department of Biostatistics and Epidemiology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States☆ Disclaimers: The authors declare that they have no
to disclose.
☆☆ Funding/support: This study was supported by the A
and Quality and the Stoneleigh Foundation.
⁎ Correspondence to: D. Rubin, CHOP North — Room
of Philadelphia, 34th and Civic Center Blvd, Philadelp
Tel.: +1 215 590 3815; fax: +1 267 426 0380.
⁎⁎ Correspondence to: M. Matone, CHOP North — Room
of Philadelphia, 34th and Civic Center Blvd, Philadelphia,
E-mail address: rubin@email.chop.edu (D. Rubin).
0190-7409 © 2012 Elsevier Ltd.
doi:10.1016/j.childyouth.2012.04.006
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 23 February 2012
Accepted 5 April 2012
Available online 13 April 2012
Keywords:
Psychotropic medication
Foster care
Medicaid
Background: High rates of treating children in foster care with second-generation antipsychotics, both singly
and in combination with other psychotropics, have focused public interest on the use of these medications,
and motivated some states to implement programs to curtail usage.
Objective: To estimate any antipsychotic use and psychotropic polypharmacy among children in foster care
during the last decade and to characterize interstate variation in these trends.
Design/methods: Centers for Medicare and Medicaid Services Medicaid Analytic Extract data ﬁles for 47 states
and the District of Columbia for years 2002–2007. The study sample included an average of 686,080 children
annually aged 3–18 years of age with foster care Medicaid eligibility. Repeated cross-sectional design con-
ducted with multilevel logistic regression, clustered at the state level and controlling for patient demo-
graphics. Main outcome measures were rates of ﬁlled prescriptions for any antipsychotic medication and
for psychotropic polypharmacy (deﬁned as concurrent use of 3 or more psychotropic medication classes
for at least 30 days during the year). State-level rate trajectories over time were classiﬁed as increased
(≥5% relative increase over interval), decreased (≥5% relative decrease over the interval), or stable.
Results: The rate of any antipsychotic use increased from 8.9% in 2002 to 11.8% in 2007 (Pb .001 for temporal
trend). In contrast, the rate of psychotropic polypharmacy was 5.2% in 2002, peaked in 2004 at 5.9%, and fell
to 5.3% in 2007 (Pb .001 for trend). State-speciﬁc rates of any antipsychotic use were signiﬁcantly increased in
45 states over the period, while rates of psychotropic polypharmacy increased in only 18 states and declined
in 19.
Conclusions: Although absolute rates of any antipsychotic use and psychotropic polypharmacy among children
in foster care remained high, psychotropic polypharmacy began to abate during the last decade, as rates of an-
tipsychotic use continued to rise.© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Children in foster care, beset by high prevalence of behavioral
health concerns (Clausen et al., 1998; Garland et al., 2000; Glisson,
1994; Halfon et al., 1995; Landsverk et al., 2002; Pecora et al., 2005;relevant ﬁnancial relationships
gency for Healthcare Research
1533, The Children's Hospital
hia, PA 10194, United States.
1536, The Children's Hospital
PA 10194, United States.
-NC-ND license.Rubin et al., 2005; Trupin et al., 1993; Urquiza et al., 1994), dispropor-
tionately use behavioral health services to a much greater degree
than other children in the community (dosReis et al., 2001; Zito
et al., 2008). While representing less than 3% of all enrollees in the
Medicaid program, children in foster care account for 25–41% of all
mental health expenditures within the Medicaid program for children
(Halfon et al., 1992; Harman et al., 2000; Takayama et al., 1994).
A large component of increased mental health expenditures among
foster care children is their increased use of psychotropic medications,
both singly and in combinations, compared to other children. Data
from the beginning of the last decade revealed that 13.5% of children
in the child welfare system were using psychotropic medications, 2–3
times the rate of other children in the community (Raghavan et al.,
2005). Furthermore, children in foster care are often exposed to psycho-
tropic polypharmacy: examination of Medicaid records from the state
1493D. Rubin et al. / Children and Youth Services Review 34 (2012) 1492–1499of Texas in 2004 revealed that 41%of children in foster carewere using 3
or more classes of psychotropicmedication within the same year, and 1
in 5 were duplicatingmedications within the same pharmacologic class
(Zito et al., 2008).
Increased use of psychotropic medications by children in foster
care occurs against a backdrop of rising use of such medications
among all children over the last two decades (Mojtabai & Olfson,
2010; Olfson et al., 2002, 2006). Federal and state policymakers
have begun to respond to the growing public debate on psychotropic
use by children, particularly for children in foster care. In 2006, a
Government Accountability Ofﬁce (GAO) report on pending chal-
lenges for the child welfare system found that 1 in 3 states identiﬁed
the use of psychotropic medication in their foster care populations as
among their most pressing issues for the next ﬁve years (Ashby,
2006). More recently, a 2011 GAO report examined psychotropic
oversight for children in child welfare in six states (Kutz, 2011). The
report found variability in adoption of oversight policies across the
states, but noted that each state had implemented at least one such
policy, though none had thoroughly adopted guidelines set forth by
a psychiatry professional board. On a national-level, by 2010, 26
states reported having a policy or guideline for use of psychotropic
medication by foster care youth and 13 states were in the develop-
ment stage of such policies or guidelines (Leslie et al., 2010).
Rates of use of the second-generation antipsychotic (SGA) medi-
cation class are of principal interest, particularly among children in
foster care, as these drugs are prescribed to address disruptive behav-
iors in children despite limited efﬁcacy data and emerging evidence
of metabolic side effects that have questioned their use in pediatric
populations (Correll, 2008; Correll et al., 2007, 2009; De Hert et al.,
2011). Between 1993 and 2002, ofﬁce visits involving the prescrip-
tion of SGAs to children and youth increased ﬁve-fold (Cooper et al.,
2006; Olfson et al., 2006). By 2003, greater than 1 in 10 foster youth
were receiving an SGA, and of those, 1 in 5 were receiving duplication
of this class (dosReis et al., 2011).
The impact of states' responses regarding psychotropic medication
use, particularly of SGAs, among children in foster care is unknown. We
therefore sought to estimate state-speciﬁc trajectories in psychotropic
use in this high-risk population and to characterize interstate variation
in these trajectories during the last decade.
2. Methods
2.1. Design and sample selection
The data source was Centers for Medicare and Medicaid Services
Medicaid Analytic Extract (MAX) data ﬁles for 50 states and theTable 1
Age-speciﬁc demographic characteristics of Medicaid-enrolled foster care children in the U
Age 3–5 (Annual average=100,000) Age 6–11 (Annu
Average
population
percentage
Across years 2002–2007
(percentage)
Average
population
percentage
Acr
(pe
High, low Percentage point change
2002 to 2007
Hig
Sex
Male 51.7 51.8, 51.6 +0.1 51.7 51
Female 48.3 48.4, 48.2 −0.1 48.3 48
Raceb
White 49.7 50.5 47.9 +2.3 47.4 48
Black 32.5 36.5, 29.9 −6.6 37.1 40
Hispanic 13.5 15.5, 11.9 +4.6 11.6 13
Other 4.3 4.5, 3.7 +0.8 3.9 4.1
Chronic conditions
Mental retardation 0.7 0.8, 0.6 −0.2 1.0 1.2
Seizure disorder 1.0 1.1, 1.0 −0.1 1.0 1.0
a 3 U.S. states not represented (Connecticut, Massachusetts, Maine).
b Children with race classiﬁed as unknown excluded (7%).District of Columbia for years 2002 through 2007. Child-level demo-
graphic, eligibility, encounter, and pharmacy data were extracted
from the personal summary, outpatient, inpatient, and pharmacy
MAX ﬁles. Medicaid eligibility category was used as the basis for clas-
sifying youth in foster care. Youth were classiﬁed as foster care in a
given year if they had at least one month of a foster care Medicaid
eligible category in the year. The sample was restricted to foster care
children aged 3–18 years of age with continuous Medicaid eligibility,
deﬁned as 10 of 12 months in a given year. Although this restriction re-
moved 31% of potential children in foster care from the analysis, sepa-
rate sensitivity analyses of this non-continuously eligible population
revealed similar levels of psychotropic medication use and trajectories
of prescribing over the period (data not shown). Because of uncertainty
around coverage and service receipt during periods of disenrollment,
we have chosen to report trends on only continuously enrolled children.
The dependent variables were a) use of a second-generation anti-
psychotic (SGA) and b) psychotropic polypharmacy, deﬁned as the con-
current use of ≥3 psychotropic medication classes during the year.
Concurrent usewas deﬁned as overlapping use of≥3 psychotropic clas-
ses 30 days or more. Psychotropic classes included stimulants, antide-
pressants, SGAs, sedative/hypnotics, anxiolytics, mood-stabilizers, and
alpha agonists. Antidepressants included selective serotonin reuptake
inhibitors (SSRI), tricyclic antidepressants (TCA), and other antidepres-
sants. Mood-stabilizing agents included carbamazepine, valproic acid,
gabapentin, lamotrigine, and oxcarbazepine anticonvulsants and lithi-
um. Since alpha-agonists, such as clonidine and guanfacine, can also
be prescribed for medical conditions, these agents were only included
in the analysis if a youth also had a claim for a psychotropic medication
in one of the above-mentioned classes. Sedatives/hypnotics excluded
antihistamines, which in pediatric practice most often have a non-
psychiatric indication for use.
Independent variables included demographic information (age,
race/ethnicity, sex, state of residence), psychiatric diagnoses, and a
count of mental health encounters. Age was categorized within calen-
dar years as 3 to 5 years, 6 to 11 years, and 12 to 18 years. Race/eth-
nicity was coded as white, black or African American, Latino, or
other. Children with race classiﬁed as unknown were excluded from
the analysis (n=313,493; 7%). Eight states (IA, MT, MN, OK, NY, RI,
VT, WI) had >15% of the state eligible population excluded as race un-
known; sensitivity analyses for these states showed equivalent trajecto-
ries of psychotropic use over the study period. In two states (NY,WI), the
levels of use differed slightly depending on the outcome — the direction
of the differences varied by state (data not shown). Psychiatric diagnoses
were coded using the International Classiﬁcation of Diseases, Ninth Revi-
sion classiﬁcation. Diagnostic categories included schizophrenia (295),
bipolar disorder (296.00–296.10, 296.36–296.89), depression (296.20–nited Statesa.
al average=237,000) Age 12–18 (Annual average=349,000)
oss years 2002–2007
rcentage)
Average
population
percentage
Across years 2002–2007
(percentage)
h, low Percentage point change
2002 to 2007
High, low Percentage point change
2002 to 2007
.8, 51.6 −0.1 51.9 52.1, 51.8 +0.1
.4, 48.2 +0.1 48.1 48.3, 48.0 −0.1
.9, 46.0 +2.9 47.9 49.8, 46.6 −3.2
.5, 33.8 −6.7 39.2 39.5, 38.2 +1.3
.2, 10.1 +3.1 9.6 10.6, 8.8 +1.8
, 3.4 +0.7 3.3 3.5, 3.2 +0.2
, 0.9 −0.3 1.4 1.5, 1.3 −0.1
, 0.9 0.0 0.8 0.9, 0.8 +0.1
Table 2
Age-speciﬁc annual frequencies in thousands (%) of mental health diagnoses among
Medicaid-enrolled foster care children in the United States.
3–5 years
2002 2003 2004 2005 2006 2007
N=91.4 N=95.1 N=98.1 N=102.7 N=106.0 N=108.4
Diagnoses
ADHD 5.1
(5.6)
5.8
(6.1)
6.2
(6.3)
6.3
(6.2)
6.7
(6.3)
6.7
(6.1)
Anxiety 0.7
(0.8)
0.9
(0.9)
1.0
(1.0)
1.3
(1.1)
1.3
(1.2)
1.5
(1.3)
Autism 0.6
(0.7)
0.7
(0.7)
0.8
(0.8)
0.9
(0.9)
1.0
(1.0)
1.1
(1.0)
Bipolar 0.2
(0.2)
0.3
(0.3)
0.3
(0.3)
0.6
(0.5)
0.4
(0.4)
0.4
(0.4)
Conduct 4.8
(5.3)
5.4
(5.7)
6.1
(6.2)
6.8
(6.6)
7.2
(6.8)
7.4
(6.8)
Depression 0.6
(0.7)
0.8
(0.9)
0.7
(0.7)
0.9
(0.9)
0.8
(0.7)
0.7
(0.7)
Schizophrenia 0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.1
(0.1)
0.0
(0.0)
0.0
(0.0)
6–11 years
2002 2003 2004 2005 2006 2007
N=231.0 N=230.4 N=233.4 N=237.8 N=241.2 N=245.5
Diagnoses
ADHD 41.6
(18.0)
44.1
(19.1)
46.5
(19.9)
48.9
(20.6)
50.4
(20.9)
52.5
(21.4)
Anxiety 4.0
(1.8)
4.5
(1.8)
4.9
(2.0)
5.6
(2.2)
5.9
(2.3)
6.6
(2.5)
Autism 1.9
(0.8)
1.9
(0.8)
2.1
(0.9)
2.4
(1.0)
2.8
(1.2)
3.0
(1.2)
Bipolar 3.3
(1.4)
4.1
(1.6)
4.7
(1.9)
5.8
(2.3)
5.6
(2.2)
5.8
(2.2)
Conduct 22.9
(9.9)
23.5
(10.2)
24.1
(10.3)
25.1
(10.6)
25.8
(10.7)
26.8
(10.9)
Depression 10.0
(4.3)
10.0
(4.3)
9.8
(4.2)
10.1
(4.3)
9.1
(3.8)
8.8
(3.6)
Schizophrenia 0.4
(0.2)
0.3
(0.1)
0.3
(0.1)
0.6
(0.3)
0.3
(0.1)
0.3
(0.1)
12–18 years
2002 2003 2004 2005 2006 2007
N=311.4 N=330.4 N=348.8 N=362.6 N=369.3 N=372.6
Diagnoses
ADHD 40.7
(13.1)
47.4
(14.4)
54.0
(15.5)
60.1
(16.6)
63.6
(17.2)
65.9
(17.7)
Anxiety 7.0
(2.3)
8.6
(2.4)
9.5
(2.5)
10.5
(2.7)
11.3
(2.8)
12.1
(3.0)
Autism 1.9
(0.6)
2.2
(0.7)
2.6
(0.7)
3.0
(0.8)
3.4
(0.9)
3.8
(1.0)
Bipolar 12.5
(4.0)
15.6
(4.3)
18.5
(4.9)
22.0
(5.6)
23.7
(5.9)
25.1
(6.3)
Conduct 56.0
(18.0)
59.5
(18.0)
63.1
(18.1)
67.1
(18.5)
68.5
(18.5)
67.3
(18.1)
Depression 38.5
(12.4)
42.0
(12.7)
44.7
(12.8)
46.8
(12.9)
46.1
(12.5)
44.4
(11.9)
Schizophrenia 2.1
(0.7)
2.2
(0.7)
2.3
(0.7)
2.7
(0.8)
2.4
(0.6)
2.3
(0.6)
1494 D. Rubin et al. / Children and Youth Services Review 34 (2012) 1492–1499296.35, and 311), anxiety disorder (300.00–300.29 and 301.4), conduct
disorder (312.00–313.89), autism (299), and attention-deﬁcit disorder
(314). Separate covariateswere identiﬁed for childrenwho received a di-
agnosis ofmental retardation (317–319) or seizure disorder (345). Iden-
tifying seizure disorderwas particularly important given the overlapping
use of anticonvulsant agents for mood stabilization.
To ensure a level of comparability across states, state-level data qual-
ity reviews were conducted to identify states in which data ﬁles were
incomplete or contained extreme outliers in: 1) trends of Medicaid
eligibility groups over time; or 2) proportion of children with mental
health diagnoses over time. Following review, three states were
deemed ineligible for use in this study: Connecticut, Massachusetts,
and Maine. Outpatient mental health claims were unavailable in CT
MAX ﬁles; foster care eligibility was unidentiﬁable in the MA MAX
ﬁles; and the 2005–2007 outpatient ﬁles were unavailable for ME.
2.2. Statistical analyses
Demographic, clinical, andmedication use characteristicswere sum-
marized as frequencies across year and categories of age (3–18). Includ-
ed in these descriptive analyses were the proportions of other major
psychotropic medication classes as a means of comparison against
the observed rates of SGA and polypharmacy use. Generalized linear
models (logit link) with a state-year interaction were then used to esti-
mate state-level variation in medication use among children over time.
Results were standardized by child-level characteristics, including age
group, gender, race, diagnosis of mental retardation, and diagnosis of
seizure disorder. Results were transformed into probabilities within
state using predictive margins (Graubard & Korn, 1999). The resulting
standardized probabilities of SGA and polypharmacy receipt were
then used to characterize change over time within state. An annual in-
crease was deﬁned as a relative increase of ≥5% from one year to the
next; an annual decrease was deﬁned as a relative decrease of≥5%; an-
nual relative change of b5%; was categorized as no change. The analysis
for children with non-continuous coverage used analogous log-linear
models but with an offset for the number of months of eligibility per
year (data not shown).
Analyses were conducted using Stata version 12.0 (College Station,
TX; 2011) and SAS v9.2 (SAS Institute, Cary NC; 2011). The Institutional
Review Board at the Children's Hospital of Philadelphia approved this
study.
3. Results
An average of 686,080 children were identiﬁed as continuously eli-
gible foster care youth within any given year from 2002 to 2007. Of
these children, 15% were aged 3–5 years, 34% 6–11 years, and 51%
12–18 years; 52% were male. Nearly half children were white (48%),
with the remaining classiﬁed as Black (37%), Hispanic (11%) or other
(4%). Mental retardation and/or seizure disorder were identiﬁed in 1%
of the study population (Table 1).
Between 2002 and 2007, and across age groups, rates of major
mental health diagnoses increased for most conditions (Table 2). De-
pression and schizophrenia were two exceptions to this trend; rates
of depression diagnosis were stable from 2002 to 2005, but exhibited
a decrease from 2006 to 2007, and rates of schizophrenia remained
stable over the period. Age-speciﬁc prevalence rates were slightly
variable. Among 3–5 year olds, the most prevalent diagnoses were
ADHD and conduct disorder (2007 rates: 6.1% and 6.8%, respectively).
In the population aged 6–11, the prevalence of ADHD diagnoses far
exceeded that of six other mental health diagnoses and experienced
the largest absolute increase over the period (18.0% to 21.4%).
Among 12–18 year olds, conduct disorder was the most frequent di-
agnosis, peaking in 2007 at 18.1%. Rates of ADHD experienced the
largest growth among this age group, rising from 13.1% to 17.7%.The unadjusted rates of medication use appear in Table 3. Across
age groups, rates of any psychotropic use experienced a rise-and-fall
trajectory, such that rates increased through 2004, but declined
thereafter through 2007. Polypharmacy use followed a similar trajec-
tory. Among individual medication classes, most classes (inclusive of
stimulants, antidepressants, and mood stabilizers) followed a similar
rise-and-fall trajectory. SGAs and alpha agonists, however, were the
only classes to experience a continuous increase over the period for
children aged 6–11 years and 12–18 years. Although trajectories
were consistently up for both of these classes, the absolute increases
Table 3
Age-speciﬁc annual frequencies in thousands (%) of psychotropic medication use among Medicaid-enrolled foster care children in the United States.
3–5 years
2002 2003 2004 2005 2006 2007
N=91.4 N=95.1 N=98.1 N=102.7 N=106.0 N=108.4
Medication class
Alpha agonista 1.6
(1.8)
1.8
(1.9)
2.1
(2.1)
2.2
(2.1)
2.2
(2.1)
2.1
(2.0)
Antidepressant 1.5
(1.7)
1.5
(1.6)
1.2
(1.3)
1.1
(1.1)
1.1
(1.0)
0.9
(0.8)
Second-generation antipsychotic 1.6
(1.7)
2.1
(2.2)
2.4
(2.4)
2.5
(2.4)
2.6
(2.4)
2.4
(2.2)
Mood stabilizer 1.3
(1.4)
1.3
(1.4)
1.3
(1.3)
1.3
(1.3)
1.3
(1.2)
1.1
(1.0)
Stimulant 4.2
(4.6)
4.9
(5.2)
5.1
(5.2)
5.0
(4.9)
5.0
(4.7)
4.6
(4.2)
Psychotropic medicationb 6.7
(7.4)
7.4
(7.8)
7.7
(7.8)
7.6
(7.4)
7.7
(7.3)
7.1
(6.5)
Polypharmacy 0.6
(0.7)
0.7
(0.7)
0.7
(0.8)
0.7
(0.7)
0.7
(0.7)
0.7
(0.6)
6–11 years
2002 2003 2004 2005 2006 2007
N=231.0 N=230.4 N=233.4 N=237.8 N=241.2 N=245.5
Medication class
Alpha agonist 13.8
(6.0)
14.0
(6.1)
14.3
(6.1)
15.2
(6.4)
16.3
(6.8)
17.4
(7.1)
Antidepressant 23.5
(10.2)
22.7
(9.9)
19.5
(8.3)
16.5
(6.9)
15.4
(6.4)
14.0
(5.7)
Second-generation antipsychotic 18.2
(7.9)
20.5
(8.9)
22.1
(9.5)
23.5
(9.9)
24.2
(10.0)
24.8
(10.1)
Mood stabilizer 10.6
(4.6)
10.9
(4.7)
10.7
(4.6)
10.6
(4.5)
10.3
(4.3)
9.8
(4.0)
Stimulant 48.3
(20.9)
52.5
(22.8)
54.9
(23.6)
56.5
(23.8)
56.4
(23.4)
55.2
(22.5)
Psychotropic medication 61.5
(26.6)
64.4
(28.0)
65.6
(28.1)
67.2
(28.2)
67.2
(27.8)
66.3
(27.0)
Polypharmacy 11.8
(5.1)
12.7
(5.5)
12.8
(5.5)
12.4
(5.2)
12.3
(5.1)
11.9
(4.9)
12–18 years
2002 2003 2004 2005 2006 2007
N=311.4 N=330.4 N=348.8 N=362.6 N=369.3 N=372.6
Medication class
Alpha agonist 12.5
(4.0)
13.6
(4.1)
14.6
(4.2)
15.8
(4.4)
16.8
(4.6)
17.8
(4.8)
Antidepressant 61.9
(19.9)
66.6
(20.2)
65.0
(18.6)
59.7
(16.5)
57.1
(15.5)
53.7
(14.4)
Second-generation antipsychotic 36.3
(11.7)
43.5
(13.2)
49.8
(14.3)
54.1
(14.9)
56.5
(15.3)
58.3
(15.6)
Mood stabilizer 27.5
(8.8)
30.3
(9.2)
32.0
(9.2)
33.2
(9.2)
33.0
(8.9)
32.1
(8.6)
Stimulant 48.0
(15.4)
58.3
(17.6)
66.8
(19.2)
72.5
(20.0)
74.4
(20.2)
72.8
(19.5)
Psychotropic medication 99.4
(31.9)
110.7
(33.5)
118.2
(33.9)
122.7
(33.9)
124.3
(33.7)
123.1
(33.0)
Polypharmacy 20.5
(6.6)
24.4
(7.4)
26.6
(7.6)
27.0
(7.5)
27.0
(7.3)
26.1
(7.0)
a Alpha agonist use was coded only when an additional claim for psychotropic medication use was present within the year for a given child.
b Psychotropicmedication includes any claim for alpha agonists, antidepressants, antipsychotics, anxiolytics,mood stabilizers, second-generation antipsychotics, sedative/hypnotics, or
stimulants.
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to 15.6% among 12–18 year olds) eclipsed the absolute increase in
alpha-agonist use (from 6.0% to 7.1% among 6–11 year olds, and
from 4.0% to 4.8% among 12–18 year olds). Rates among 3–5 year
olds for SGAs and alpha-agonists rose slightly early in the period,
but had leveled off or declined slightly in later years (2005–2007).
At a state-level (Table 4), 45 states experienced a relative increase in
rates of SGA use over the 6-year period. Two states experienced a rela-
tive decrease, and one state experienced no change over the period.Relative increases among states varied widely, ranging from 72.0% to
6.4%. Furthermore, absolute levels of antipsychotic use in 2007 were
variable and ranged from 21.7% to 2.8%, with a median rate of 12.8%.
Examining year-to-year change, some state-level rates increased con-
sistently from year to the next, while others did not change or declined
(Fig. 1). In any given year (compared to the prior year), the number of
states experiencing an increase in SGA use declined from 42 in 2003
to 13 in 2007, while the number of states experiencing a decrease in
SGA use rose from 3 to 9 over the period.
Table 4
Trajectoriesa of second-generation antipsychotic (SGA) use among Medicaid-enrolled foster care children in the United States between 2002 and 2007; by state.
2002–2007 increase
State 2002 population 2002 rateb 2003 2004 2005 2006 2007 2007 rate 2007 population Percent change 2007–2002
AR 4191 0.105 + + . + + 0.181 5439 71.9%
SD 1995 0.079 + + + + + 0.136 2656 71.0%
RI 3740 0.054 + + + . + 0.090 2983 68.0%
WA 12,095 0.042 + + + . + 0.071 14,579 67.9%
AZ 6573 0.077 − + . + . 0.126 11,109 64.1%
MN 7568 0.076 + + + . . 0.118 6729 55.9%
TN 11,773 0.070 + + + . . 0.109 15,553 54.9%
MT 3132 0.083 + + + . . 0.128 3437 54.3%
AL 4631 0.091 + + + . . 0.139 6227 52.2%
MI 29,789 0.075 + + + . . 0.112 32,266 48.9%
CA 130,765 0.055 + + + . . 0.081 126,171 48.4%
OK 12,481 0.100 + + . . + 0.148 11,685 48.3%
DE 1431 0.122 + + + + . 0.178 1796 45.9%
VT 1470 0.085 + + + . − 0.123 1576 45.1%
IL 57,707 0.069 + − + + + 0.099 49,332 44.6%
WY 1449 0.087 − + + + . 0.126 2169 44.1%
SC 7067 0.057 + + + + . 0.081 9841 41.3%
WI 8663 0.086 + + . . . 0.121 8228 41.3%
OR 10622 0.065 + . . . + 0.091 12,540 40.8%
VA 8356 0.129 + + . . + 0.180 12,038 39.4%
AK 1633 0.089 + − + . + 0.122 2754 36.6%
ID 1735 0.104 + + + . . 0.141 2545 36.5%
NC 13,291 0.094 + + . . + 0.127 16,952 35.6%
NE 8425 0.127 + + . . . 0.172 10,666 35.6%
WV 5106 0.073 + + + − + 0.099 6325 35.1%
NM 3060 0.077 + + + + . 0.103 4489 34.9%
MD 13,319 0.122 . + + + . 0.164 13,525 33.8%
DC 3554 0.106 + + . + − 0.139 3094 31.5%
NV 3436 0.105 + . . . + 0.137 5609 31.1%
NY 13,327 0.085 + + . . . 0.109 17,833 28.1%
GA 15,904 0.109 + + . . . 0.140 25,770 28.0%
KS 9369 0.152 + + . . . 0.193 11,382 27.1%
UT 4341 0.102 + . . + . 0.129 6150 26.1%
FL 32,246 0.072 + + + . . 0.089 35,781 25.0%
LA 7845 0.116 + + . − . 0.144 10,003 23.7%
IN 11,476 0.124 + + . − . 0.153 15,346 23.4%
KY 7876 0.153 + + − . . 0.182 11,150 18.7%
OH 21,828 0.105 + . + . . 0.124 26,769 18.2%
PA 38,860 0.060 − + . + + 0.070 44,841 17.1%
ND 1353 0.114 + . . . − 0.133 1513 16.2%
NH 2216 0.114 + + . . − 0.129 2297 13.0%
NJ 15,395 0.097 . − + . . 0.106 20,028 9.8%
CO 10,723 0.117 + + − − − 0.128 13,201 9.6%
IA 7270 0.142 + . . . . 0.154 6558 8.5%
MO 21,973 0.148 + . . . . 0.157 24,063 6.4%
2002–2007 no change
State 2002 population 2002 rate 2003 2004 2005 2006 2007 2007 rate 2007 population Percent change 2007–2002
MS 2642 0.123 . − . − . 0.120 4006 −2.8
2002–2007 decrease
State 2002 population 2002 rate 2003 2004 2005 2006 2007 2007 rate 2007 population Percent change 2007–2002
TX 26,131 0.237 + . − . − 0.217 41,711 −8.4
HI 3961 0.032 + + . . − 0.028 5897 −11.7
a Annual increase deﬁned as relative change of ≥5% increase; annual decrease deﬁned as relative change of ≥5% decrease; annual no change deﬁned as relative change b5%.
b Annual rate expressed as a proportion of Medicaid-enrolled foster care children aged 3–18 with at least one ﬁlled claim for SGA in the year, standardized on patient character-
istics of sex, age group, race, and chronic conditions (seizure disorder and mental retardation).
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demonstrated an increase in polypharmacy use between 2002 and
2007. While 18 states experienced an increase in polypharmacy use,
19 experienced a decrease, and 11 experienced no change (Table 5).
Relative increases ranged from 34.48% to 6.7%, while relative de-
creases ranged from −5.3% to −66.7%. Similar to antipsychotics,
wide variability existed in states' absolute levels of polypharmacy in
2007 (13.6% to 0.5%) (Table 5). Year-to-year changes in polyphar-
macy use for each state were also considerably different than for
SGA use (Fig. 1). The number of states with an annual increases inpolypharmacy use declined from 32 in 2003 to 2 in 2007. Conversely,
the number of states with decreased polypharmacy use from the pre-
vious year rose from 4 in 2003 to 19 in 2007.
4. Discussion
This national study revealed signiﬁcant state variation in both
polypharmacy and SGA use by children in foster care, and detected
a changing trend in their use in this population. Although overall
rates of psychotropic medication use remained high, many states
Table 5
Trajectoriesa of polypharmacy use among Medicaid-enrolled foster care children in the United States between 2002 and 2007; by state.
2002–2007 increase
State 2002 population 2002 rateb 2003 2004 2005 2006 2007 2007 rate 2007 population Percent change 2007–2002
WA 12,095 0.029 + . . . . 0.039 14,579 34.48%
NM 3060 0.037 . . + + . 0.046 4489 24.32%
OK 12,481 0.05 + . − . + 0.062 11,685 24.00%
MN 7568 0.053 + . + . + 0.065 6729 22.64%
MI 29,789 0.042 + + + . . 0.05 32,266 19.05%
AR 4191 0.07 . + . + . 0.083 5439 18.57%
AL 4631 0.062 + + + . . 0.072 6227 16.13%
NY 13,327 0.019 + + . − − 0.022 17,833 15.79%
GA 15,904 0.065 + + − − . 0.074 25,770 13.85%
NC 13,291 0.052 + + − . . 0.059 16,952 13.46%
UT 4341 0.058 + + − . − 0.065 6150 12.07%
MT 3132 0.042 . . + . . 0.047 3437 11.90%
AZ 6573 0.059 − + − . . 0.065 11,109 10.17%
SD 1995 0.042 + + − . . 0.046 2656 9.52%
ID 1735 0.057 + + − . . 0.062 2545 8.77%
WI 8663 0.057 + . . . − 0.062 8228 8.77%
RI 3740 0.036 + . − . − 0.039 2983 8.33%
VA 8356 0.09 . + . . . 0.096 12,038 6.67%
2002–2007 no change
State 2002 population 2002 rate 2003 2004 2005 2006 2007 2007 rate 2007 population Percent change 2007–2002
CA 130,765 0.023 + . . . . 0.024 126,171 4.35%
OR 10,622 0.027 + . . − . 0.028 12,540 3.70%
DE 1431 0.079 + − . + − 0.081 1796 2.53%
IL 57,707 0.041 + − + . . 0.042 49,332 2.44%
IA 7270 0.087 + . − . − 0.089 6558 2.30%
WV 5106 0.051 . . − . . 0.052 6325 1.96%
OH 21,828 0.064 + . . . − 0.065 26,769 1.56%
KY 7876 0.085 + . − . . 0.086 11,150 1.18%
VT 1470 0.055 . . + . − 0.053 1576 −3.64%
NE 8425 0.082 + . − . − 0.078 10,666 −4.88%
MD 13,319 0.081 + . . . − 0.077 13,525 −4.94%
2002–2007 decrease
State 2002 population 2002 rate 2003 2004 2005 2006 2007 2007 rate 2007 population Percent change 2007–2002
KS 9369 0.095 + + . − . 0.09 11,382 −5.26%
AK 1633 0.057 . + − − . 0.053 2754 −7.02%
TNc 11,773 n/a n/a + − − − 0.049 15,553 −8.07%
DC 3554 0.062 + − − . − 0.056 3094 −9.68%
CO 10,723 0.061 + . − − . 0.055 13,201 −9.84%
NH 2216 0.071 . . − . . 0.063 2297 −11.27%
IN 11,476 0.081 + + − . . 0.071 15,346 −12.35%
MO 21,973 0.098 + . − . . 0.085 24,063 −13.27%
WY 1449 0.057 − + . − − 0.049 2169 −14.04%
LA 7845 0.084 + . − − . 0.072 10,003 −14.29%
SC 7067 0.052 . . . . − 0.044 9841 −15.38%
ND 1353 0.087 + − − . − 0.073 1513 −16.09%
PA 38,860 0.03 − . − . . 0.025 44,841 −16.67%
FL 32,246 0.042 + − − − − 0.033 35,781 −21.43%
NJ 15,395 0.049 . − . − . 0.038 20,028 −22.45%
NV 3436 0.06 + . . − − 0.046 5609 −23.33%
TX 26,131 0.181 + . − . − 0.136 41,711 −24.86%
MS 2634 0.061 . − − − . 0.041 3931 −32.79%
HI 3961 0.015 − + − + − 0.005 5897 −66.67%
a Annual increase deﬁned as relative change of ≥5% increase; annual decrease deﬁned as relative change of ≥5% decrease; annual no change deﬁned as relative change b5%.
b Annual rate expressed as a proportion of Medicaid-enrolled foster care children aged 3–18 with ﬁlled claims for ≥3 psychotropic medication classes overlapping for at least
30 days in the year, standardized on patient characteristics of sex, age group, race, and chronic conditions (seizure disorder and mental retardation).
c Data projected from 2003 to 2007 due to limited availability of data on stimulants in 2002.
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by 2007, in contrast to reports from prior years that had suggested
consistent increases (Bhatara et al., 2004; Mojtabai & Olfson, 2010;
Safer & Zito, 2003). Despite the decrease in polypharmacy prescrib-
ing, SGA use continued to increase over this time period, albeit with
a reduced trajectory of growth by 2007. Notably, 2005 seems to
have been a pivotal year. Not only did polypharmacy use in most
states ebb signiﬁcantly starting in 2005, but also, the increase in
SGA use ﬂattened, with many states showing no interval increases
in SGA use across years beyond 2005.The change in psychotropic use among children in foster care that
was observed during the last decade should be interpreted cautiously.
The waning of polypharmacy use beyond 2005, for example, was
quite variable across states, and overall rates for many states remained
quite high—1 in 14 adolescents were receiving polypharmacy by 2007.
Nevertheless, why such rates began to decline inmany states will likely
invite speculation. Whether increased public dialogue, epidemiologic
changes in the spectrum of illness, changing provider practice, avail-
ability of alternative therapies, or state-speciﬁc policy responses
effected these changes might be difﬁcult to disaggregate. Similarly,
Annual increase defined as relative change of    5%; annual decrease defined as relative change of    5%; annual no change defined as
relative change <5%  
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Fig. 1. State-level annual changes in rates of second-generation antipsychotic (A) and polypharmacy (B) among Medicaid-enrolled foster care children aged 3–18 years.
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should be also be interpreted with caution, particularly given the dy-
namic nature of the SGA market in later half of the past decade.
Speciﬁcally, broadened approval of quetiapine (Seroquel) and aripi-
prazole (Abilify) for indications other than schizophrenia during the
study period could potentially have inﬂuenced trends beyond 2007.
Although the increasing trajectory of SGA use was beginning to
slow in most states, it is certainly possible that the introduction of
newer agents within this class might have led to state increases in
SGA use – or perhaps even polypharmacy – beyond 2007.
This study has other limitations that also should be considered.
First, while the study characterizes the state-speciﬁc trends in the
use of psychotropic medications by children in foster care, it cannot
describe at a case-level whether the treatment decisions were appro-
priate or inappropriate; nor can it describe the pattern of medications
used by individual children. Second, it is possible that the children
identiﬁed as foster care youth were misclassiﬁed among the state
populations in this study, since administrative Medicaid-eligibility
codes might misclassify children. A prior report, for example, sug-
gested that eligibility codes for children in foster might over-count
children receiving services (Rubin et al., 2009). However, the average
of 686,000 children who were identiﬁed as foster care youth in any
given year is reassuring, given that it is represents nearly 90% of
known numbers of children traversing the system (U.S. Children's
Bureau, Administration for Children, Youth and Families, 2011). Fur-
thermore, to the degree that within state and across time any potential
biases are consistent, they would be unlikely to change the observed
trajectories even if they might bias the point estimates. The latter
concern would caution against use of these data as a point-in-time re-
port cards for states, but would not impact the interpretation of their
trajectories.
Although the trajectories estimated in this study might refocus con-
cern about psychotropic medication utilization, interpreting these ﬁnd-
ings is complex. Even a modest decline in the use of polypharmacy, for
example, does not negate the reality that 5.3% of foster care children
across the countrywere using a combination of three ormore psychotro-
pic medications, and 11.8% were using SGAs in 2007: these facts should
remain a signiﬁcant source of continued scrutiny. Furthermore, the sub-
stantial variation detected across states suggests that children's location
within the systems of public health and childwelfaremightmattermore
than their underlying health issues in determining the likelihood of re-
ceiving psychotropics. Finally, even as polypharmacy has begun to de-
cline, the relative increase in antipsychotic use might represent the
substitution of single-drug treatment strategy with SGAs for disruptive
behaviors in lieu of previous psychotropic polypharmacy patterns of
using SGAs as an adjuvant with other psychotropic medications.Nevertheless, characterizing the use of psychotropic medication
by foster youth as increasing, particularly regarding psychotropic
polypharmacy, might no longer be correct. Years of public dialogue,
and potentially state responses, might be inﬂuencing provider behav-
ior in the use of psychotropic medications. Examining trends beyond
2007 will be important, as will characterizing which combinations of
medications (or single-use regimens) are becoming the most preva-
lently prescribed for foster care youth over time. Furthermore, while
this study reveals that trendsmight be changing inmany states, wheth-
er the outcomes for children are changing remains unknown. Stateswill
need tomonitor child-level outcomes, aswell as the alternative services
provided by behavioral health systems, as they increasingly investigate
and reﬁne policies on the use of psychotropic medications.Acknowledgments
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